Hengrui licenses oral weight-loss drug to Novo Nordisk in $2.6B deal

China's Hengrui Pharma has licensed an experimental once-weekly oral weight-loss drug to Denmark's Novo Nordisk in a deal valued up to $2.6 billion. The agreement signals a major cross-border pharma deal and underscores the competitive dynamics in the obesity drug market. Financial terms and clinical milestones remain undisclosed, and the drug's regulatory approval is uncertain.